

Supplementary materials

Rocatinlimab improves patient-reported outcomes in adults with moderate-to-severe atopic dermatitis: results from a double-blind placebo-controlled phase 2b study

Melinda Gooderham,^a Emma Guttman-Yassky,^b Ken Igawa,^c Kenji Kabashima,^d Ehsanollah Esfandiari,^e Angela J Rylands,^e Angela Williams,^e Annabel Nixon,^f Jennifer E Dent,^f Eric Simpson^g

^aSKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, Ontario, Canada

^bIcahn School of Medicine at Mount Sinai, USA

^cDokkyo Medical University, Mibu, Japan

^dKyoto University, Japan

^eKyowa Kirin International, UK

^fChilli Consultancy, Salisbury, UK

^gOregon Health and Science University, USA

Corresponding author

Melinda Gooderham

SKiN Centre for Dermatology

775 Monaghan Road

Peterborough

Ontario

Canada

Email: mgooderham@centrefordermatology.com

Supplementary Table 1 PRO scores at baseline (n=267)

PRO		Possible range	Mean \pm SD (range)	Median (Q1, Q3)
Pruritus NRS		0–10	7.5 \pm 1.9 (1–10)	8 (7, 9)
Sleep Disturbance NRS		0–10	5.5 \pm 2.9 (0–10)	6 (3, 8)
DLQI	Total score	0–30	12.6 \pm 7.1 (0–30)	11 (7, 18)
	Symptoms and feelings	0–6	4.0 \pm 1.4 (0–6)	4 (3, 5)
	Daily activities	0–6	2.8 \pm 1.7 (0–6)	3 (1, 4)
	Leisure	0–6	2.1 \pm 1.9 (0–6)	2 (0, 3)
	Work and school	0–3	1.3 \pm 1.1 (0–3)	1 (0, 2)
	Personal relationships	0–6	1.2 \pm 1.6 (0–6)	1 (0, 2)
	Treatment	0–3	1.2 \pm 1.0 (0–3)	1 (0, 2)
Higher NRS scores indicate greater severity of pruritus/sleep loss. Higher DLQI scores indicate greater HRQL impairment. DLQI, Dermatitis Life Quality Index; NRS, Numerical Rating Scale; PRO, patient-reported outcome; Q, quartile; SD, standard deviation.				

Supplementary Table 2 Variation in DLQI scores by demographic characteristics at baseline (n=267)

Subject characteristic	n	Domain scores												Total score	
		Symptoms and feelings		Daily activities		Leisure		Work and school		Personal relationships		Treatment			
		Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a
Age (years)	267	na	0.09	na	0.09	na	-0.01	na	-0.13	na	0.12	na	0.03	na	0.03
Sex															
Female	109	4.4 (1.4)	na	3.2 (1.8)	na	2.6 (2.1)	na	1.3 (1.2)	na	1.6 (1.8)	na	1.3 (1.0)	na	14.9 (7.7)	na
Male	158	3.8 (1.4)	na	2.5 (1.7)	na	1.8 (1.8)	na	1.2 (1.1)	na	0.9 (1.4)	na	1.1 (0.9)	na	11.3 (6.5)	na
Country															
Canada	25	4.1 (1.6)	na	3.0 (1.9)	na	2.0 (1.8)	na	0.8 (1.1)	na	1.7 (1.8)	na	1.3 (1.0)	na	13.3 (7.9)	na
Germany	33	4.6 (1.2)	na	3.5 (1.5)	na	3.7 (2.0)	na	1.3 (1.2)	na	2.8 (1.8)	na	1.4 (1.1)	na	18.8 (7.2)	na
Japan	155	3.8 (1.4)	na	2.2 (1.6)	na	1.5 (1.5)	na	1.2 (1.1)	na	0.5 (0.9)	na	1.0 (0.9)	na	10.3 (6.0)	na
USA	54	4.4 (1.5)	na	3.6 (1.7)	na	3.1 (2.1)	na	1.7 (1.2)	na	1.8 (1.8)	na	1.6 (0.9)	na	16.7 (6.7)	na
Race															
Asian	171	3.8 (1.4)	na	2.3 (1.7)	na	1.6 (1.7)	na	1.3 (1.1)	na	0.7 (1.2)	na	1.1 (1.0)	na	10.9 (6.4)	na
Black or African American	13	4.5 (1.7)	na	3.5 (2.0)	na	2.9 (2.3)	na	1.6 (1.3)	na	2.0 (1.9)	na	1.2 (1.1)	na	16.7 (8.2)	na
White	82	4.5 (1.3)	na	3.5 (1.6)	na	3.0 (2.0)	na	1.3 (1.2)	na	2.1 (1.8)	na	1.5 (0.9)	na	16.7 (7.0)	na
BMI (kg/m ²)	266	na	0.09	na	0.04	na	0.03	na	-0.10	na	0.06	na	-0.01	na	-0.01

Spearman's rank coefficients are reported for correlations between continuous/ordinal demographic/clinical variables and DLQI scores. Mean DLQI scores for categorical variables were compared using Mann-Whitney tests (two categories) or ANOVA F-test (multiple categories); significant results (p<0.05) shown in **bold**.

^aInterpretation of Spearman's rank correlation coefficient (for ordinal and continuous variables): 0.90–1.00, very high positive; 0.70–0.90, high positive; 0.50–0.70, moderate positive; 0.30–0.50, low positive; 0.00–0.30, negligible [36].

BMI; body mass index; corr, correlation; DLQI, Dermatology Life Quality Index; na, not applicable; SD, standard deviation.

Supplementary Table 3 Variation in DLQI scores by clinical characteristics at baseline (n=267)

Subject characteristic	N	Domain scores												Total score		
		Symptoms and feelings		Daily activities		Leisure		Work and school		Personal relationships		Treatment		Mean (SD)	Corr ^a	
		Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a			
Time since diagnosis	267	na	0.05	na	0.13	na	0.17	na	-0.03	na	0.23	na	0.04	na	0.17	
vIGA-AD																
3	147	3.8 (1.4)	na	2.5 (1.7)	na	2.0 (1.9)	na	1.1 (1.1)	na	1.2 (1.6)	na	1.0 (1.0)	na	11.5 (7.2)	na	
4	120	4.3 (1.3)	na	3.1 (1.7)	na	2.3 (2.0)	na	1.5 (1.1)	na	1.2 (1.6)	na	1.4 (1.0)	na	14.3 (6.8)	na	
EASI	267	na	0.20	na	0.15	na	0.13	na	0.23	na	0.06	na	0.21	na	0.19	
SCORAD	266	na	0.41	na	0.36	na	0.26	na	0.36	na	0.16	na	0.29	na	0.36	
% BSA affected	267	na	0.09	na	0.03	na	0.03	na	0.13	na	-0.11	na	0.08	na	0.02	
Biological product																
Yes	37	4.4 (1.3)	na	3.1 (1.8)	na	2.5 (2.0)	na	1.5 (1.1)	na	1.4 (1.6)	na	1.4 (1.0)	na	14.5 (7.4)	na	
No	230	4.0 (1.4)	na	2.7 (1.7)	na	2.1 (1.9)	na	1.3 (1.1)	na	1.1 (1.6)	na	1.2 (1.0)	na	12.5 (7.1)	na	
Asthma																
Yes	68	4.1 (1.4)	na	3.2 (1.8)	na	2.6 (1.9)	na	1.4 (1.1)	na	1.5 (1.8)	na	1.3 (1.0)	na	14.5 (7.3)	na	
No	199	4.0 (1.4)	na	2.6 (1.7)	na	1.9 (1.9)	na	1.3 (1.1)	na	1.1 (1.5)	na	1.2 (1.0)	na	12.1 (7.1)	na	
Allergic rhinitis																
Yes	23	4.1 (1.3)	na	3.0 (1.6)	na	2.0 (1.8)	na	1.7 (1.3)	na	1.2 (1.3)	na	1.3 (1.0)	na	13.7 (6.7)	na	
No	244	4.0 (1.4)	na	2.7 (1.8)	na	2.1 (1.9)	na	1.2 (1.1)	na	1.2 (1.6)	na	1.2 (1.0)	na	12.7 (7.2)	na	

Spearman's rank coefficients are reported for correlations between continuous/ordinal demographic/clinical variables and DLQI scores. Mean DLQI scores for categorical variables were compared using Mann-Whitney tests (two categories) or ANOVA F-test (multiple categories); significant results (p<0.05) shown in **bold**.

^aInterpretation of Spearman's rank correlation coefficient (for ordinal and continuous variables): 0.90–1.00, very high positive; 0.70–0.90, high positive; 0.50–0.70, moderate positive; 0.30–0.50, low positive; 0.00–0.30, negligible [36].

BSA, body surface area; corr, correlation; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; vIGA-AD, validated Investigator Global Assessment for Atopic Dermatitis; na, not applicable; SCORAD, SCORing Atopic Dermatitis; SD, standard deviation.

Supplementary Table 4 Variation in DLQI scores by PROs at baseline (n=267)

Subject characteristic	n	Domain scores												Total score	
		Symptoms and feelings		Daily activities		Leisure		Work and school		Personal relationships		Treatment		Mean (SD)	Corr ^a
		Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a	Mean (SD)	Corr ^a		
Worst Pruritus NRS	267	na	0.60	na	0.44	na	0.37	na	0.32	na	0.25	na	0.26	na	0.46
Sleep Disturbance NRS	267	na	0.52	na	0.51	na	0.47	na	0.45	na	0.42	na	0.37	na	0.59


Spearman's rank coefficients are reported for correlations between continuous/ordinal demographic/clinical variables and DLQI scores. Mean DLQI scores for categorical variables were compared using Mann–Whitney tests (two categories) or ANOVA F-test (multiple categories); significant results (p<0.05) shown in **bold**.

^aInterpretation of Spearman's rank correlation coefficient (for ordinal and continuous variables): 0.90–1.00, very high positive; 0.70–0.90, high positive; 0.50–0.70, moderate positive; 0.30–0.50, low positive; 0.00–0.30, negligible [36].


Corr, correlation; DLQI, Dermatology Life Quality Index; na, not applicable; NRS, Numerical Rating Scale; PRO, patient-reported outcome; SD, standard deviation.

Supplementary Figure 1 Change from baseline in DLQI domain scores (n=267)


(a) Symptoms and feelings




(b) Daily activities




(c) Leisure




(d) Work and school



(e) Personal relationships



(f) Treatment




DLQI domain scores 0–6 for Symptoms and feelings, Daily activities, Leisure, and Personal relationships, 0–3 for Work and school, and Treatment; higher scores indicate greater impairment.

BL, baseline; DLQI, Dermatology Life Quality Index; LS, least squares; Q2W, every 2 weeks; Q4W, every 4 weeks.


Supplementary Figure 2

PRO scores at study baseline (n=267)


(a) Worst Pruritus NRS



(b) Sleep Disturbance NRS




(b) DLQI domain scores



Supplementary Figure 3
(n=267)

Indicators of worse DLQI domain and total scores at baseline



Variation in HRQL by demographic and clinical variables was compared using Spearman’s Rank Correlation Coefficient for continuous/ordinal variables, Mann–Whitney (two categories), and ANOVA F-test (more than two categories). P values <0.05 were considered statistically significant.

Categories: female/male; Canada/Germany/Japan/USA, Asian/Black or African American/Asian, vIGA 3/4.

Higher DLQI scores indicate greater HRQL impairment.

↑, higher; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; NRS, Numerical Rating Scale; PRO, patient-reported outcome; SCORAD, SCORing Atopic Dermatitis; vIGA, validated Investigator Global Assessment for Atopic Dermatitis.